Accueil>>Signaling Pathways>> GPCR/G protein>> Ras>>GGTI-286

GGTI-286

Catalog No.GC64216

Le GGTI-286, un inhibiteur de la GGTase I puissant et perméable aux cellules, est 25 fois plus puissant (IC50 = 2 μM) que l'ester méthylique correspondant du FTI-276. Le GGTI-286 inhibe sélectivement la géranylgéranylation de Rap1A par rapport À la farnésylation de H-Ras dans les cellules NIH3T3 (IC50 = 2 et > 30 μM, respectivement). Le GGTI-286 inhibe également puissamment la stimulation oncogène de K-Ras4B avec une IC50 de 1 μM.

Products are for research use only. Not for human use. We do not sell to patients.

GGTI-286 Chemical Structure

Cas No.: 171744-11-9

Taille Prix Stock Qté
5 mg
468,00 $US
En stock
10 mg
765,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 . GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM[1].

[1]. E C Lerner, et al. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem. 1995 Nov 10;270(45):26770-3. [2]. Naoyuki Nishiya, et al. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/β-catenin pathway. Chem Biol. 2014 Apr 24;21(4):530-540.

Avis

Review for GGTI-286

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GGTI-286

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.